PMID- 22690902
OWN - NLM
STAT- MEDLINE
DCOM- 20121113
LR  - 20151119
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 89
IP  - 4
DP  - 2012 Oct
TI  - Bortezomib/dexamethasone followed by autologous stem cell transplantation as 
      front line treatment for light-chain deposition disease.
PG  - 340-4
LID - 10.1111/j.1600-0609.2012.01821.x [doi]
AB  - Limited data has been published on the treatment results in patients with 
      light-chain deposition disease (LCDD). Whenever possible, high-dose melphalan 
      followed by autologous stem cell transplantation (ASCT) has been the first 
      treatment option, achieving somehow better results than conventional therapy. 
      However, and based on the promising results obtained by treating patients with 
      light-chain amyloidosis with bortezomib/dexamethasone, new treatment options 
      appear in LCDD. Herein, we describe three patients with LCDD treated with 
      bortezomib/dexamethasone followed by high-dose melphalan and autologous 
      transplantation. We believe that this new approach should be the treatment of 
      choice in this disease. In addition, those patients achieving hematologic 
      complete response after ASCT could benefit from a kidney transplant if the renal 
      impairment requiring dialysis persists.
CI  - (c) 2012 John Wiley & Sons A/S.
FAU - Tovar, Natalia
AU  - Tovar N
AD  - Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clinic, 
      Barcelona, Spain.
FAU - Cibeira, Ma Teresa
AU  - Cibeira MT
FAU - Rosinol, Laura
AU  - Rosinol L
FAU - Sole, Manel
AU  - Sole M
FAU - de Larrea, Carlos Fernandez
AU  - de Larrea CF
FAU - Escoda, Lourdes
AU  - Escoda L
FAU - Rovira, Montserrat
AU  - Rovira M
FAU - Blade, Joan
AU  - Blade J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120710
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Boronic Acids)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Adult
MH  - Boronic Acids/administration & dosage/*therapeutic use
MH  - Bortezomib
MH  - Combined Modality Therapy
MH  - Dexamethasone/administration & dosage/*therapeutic use
MH  - Female
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/surgery/*therapy
MH  - Pyrazines/administration & dosage/*therapeutic use
EDAT- 2012/06/14 06:00
MHDA- 2012/11/14 06:00
CRDT- 2012/06/14 06:00
PHST- 2012/06/07 00:00 [accepted]
PHST- 2012/06/14 06:00 [entrez]
PHST- 2012/06/14 06:00 [pubmed]
PHST- 2012/11/14 06:00 [medline]
AID - 10.1111/j.1600-0609.2012.01821.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2012 Oct;89(4):340-4. doi: 10.1111/j.1600-0609.2012.01821.x. Epub 
      2012 Jul 10.